Wednesday, July 8, 2026

biotech · Moderately to Severely Active Ulcerative Colitis · Inflammatory Bowel Diseases · ODTX

Odyssey Therapeutics

Odyssey Therapeutics is a biotech organization headquartered in San Ramon, USA. It trades on NYSE under ticker ODTX. Primary therapeutic focus areas include Moderately to Severely Active Ulcerative Colitis, Inflammatory

San Ramon, USA HQ
3 Employees
Public company Type
ODTX · NYSE Ticker
Company details
Status
Public
HQ
San Ramon, USA
Employees
3
Programs
4
Drugs
6
Patents
1
Clinical program

OD-07656

Phase 1 · small molecule · Inflammatory Bowel Diseases

OD-07656 for Inflammatory Bowel Diseases is a Phase 1 program (small_molecule) at Odyssey Therapeutics with 1 ClinicalTrials.gov record(s).

← All Odyssey Therapeutics projects Phase 1 small molecule completed

Internal code OD-07656-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Odyssey Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Inflammatory Bowel Diseases
Status
completed
Trials
1

Clinical trials